• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

第十届全球肝脏磁共振成像论坛共识报告:多学科团队讨论。

Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion.

机构信息

Department of Diagnostic, Molecular, and Interventional Radiology, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.

出版信息

Eur Radiol. 2023 Dec;33(12):9167-9181. doi: 10.1007/s00330-023-09919-z. Epub 2023 Jul 13.

DOI:
10.1007/s00330-023-09919-z
PMID:37439935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10667403/
Abstract

The 10th Global Forum for Liver Magnetic Resonance Imaging was held in October 2021. The themes of the presentations and discussions at this Forum are described in detail in the review by Taouli et al (2023). The focus of this second manuscript developed from the Forum is on multidisciplinary tumor board perspectives in hepatocellular carcinoma (HCC) management: how to approach early-, mid-, and late-stage management from the perspectives of a liver surgeon, an interventional radiologist, and an oncologist. The manuscript also includes a panel discussion by multidisciplinary experts on three selected cases that explore challenging aspects of HCC management. CLINICAL RELEVANCE STATEMENT: This review highlights the importance of a multidisciplinary team approach in liver cancer patients and includes the perspectives of a liver surgeon, an interventional radiologist, and an oncologist, including illustrative case studies. KEY POINTS: • A liver surgeon, interventional radiologist, and oncologist presented their perspectives on the treatment of early-, mid-, and late-stage HCC. • Different perspectives on HCC management between specialties emphasize the importance of multidisciplinary tumor boards. • A multidisciplinary faculty discussed challenging aspects of HCC management, as highlighted by three case studies.

摘要

第十届全球肝脏磁共振成像论坛于 2021 年 10 月举行。Taouli 等人(2023 年)详细描述了本次论坛的演讲和讨论主题。本论坛第二份专题论文的重点是肝细胞癌(HCC)管理中的多学科肿瘤委员会视角:从肝外科医生、介入放射科医生和肿瘤学家的角度如何处理早期、中期和晚期管理。本文还包括多学科专家对三个选定病例的小组讨论,探讨了 HCC 管理的挑战性方面。临床相关性声明:本综述强调了多学科团队方法在肝癌患者中的重要性,包括肝外科医生、介入放射科医生和肿瘤学家的观点,包括说明性病例研究。要点:

• 一位肝外科医生、介入放射科医生和肿瘤学家介绍了他们对早期、中期和晚期 HCC 治疗的看法。

• 不同专业对 HCC 管理的观点强调了多学科肿瘤委员会的重要性。

• 多学科教员讨论了三个病例研究中突出的 HCC 管理的挑战性方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/5886f360e196/330_2023_9919_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/9eed5f24f902/330_2023_9919_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/b6dc216815e6/330_2023_9919_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/00ffafe12aec/330_2023_9919_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/c938aa1cb5db/330_2023_9919_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/6c7205a92665/330_2023_9919_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/5886f360e196/330_2023_9919_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/9eed5f24f902/330_2023_9919_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/b6dc216815e6/330_2023_9919_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/00ffafe12aec/330_2023_9919_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/c938aa1cb5db/330_2023_9919_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/6c7205a92665/330_2023_9919_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cd/10667403/5886f360e196/330_2023_9919_Fig6_HTML.jpg

相似文献

1
Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion.第十届全球肝脏磁共振成像论坛共识报告:多学科团队讨论。
Eur Radiol. 2023 Dec;33(12):9167-9181. doi: 10.1007/s00330-023-09919-z. Epub 2023 Jul 13.
2
Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management.第十届全球肝脏磁共振成像论坛共识报告:肝癌管理的新进展。
Eur Radiol. 2023 Dec;33(12):9152-9166. doi: 10.1007/s00330-023-09928-y. Epub 2023 Jul 27.
3
Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.第八届国际肝脏磁共振成像论坛共识报告。
Eur Radiol. 2020 Jan;30(1):370-382. doi: 10.1007/s00330-019-06369-4. Epub 2019 Aug 5.
4
Consensus report from the 9 International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging.来自第 9 届国际肝脏磁共振成像论坛的共识报告:钆塞酸增强成像的应用。
Eur Radiol. 2021 Aug;31(8):5615-5628. doi: 10.1007/s00330-020-07637-4. Epub 2021 Feb 1.
5
Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.钆塞酸二钠增强 MRI 在肝细胞癌管理中的诊断工具作用:2020 年亚太多学科专家会议报告。
Korean J Radiol. 2022 Jul;23(7):697-719. doi: 10.3348/kjr.2021.0593. Epub 2022 May 9.
6
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.钆塞酸 MRI 和扩散加权成像在诊断肝细胞癌早期复发中的性能。
Eur Radiol. 2020 Jan;30(1):186-194. doi: 10.1007/s00330-019-06351-0. Epub 2019 Aug 1.
7
Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology.钆塞酸二钠增强MRI诊断肝细胞癌:韩国腹部放射学会2016年共识推荐
Korean J Radiol. 2017 May-Jun;18(3):427-443. doi: 10.3348/kjr.2017.18.3.427. Epub 2017 Apr 3.
8
Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging.使用钆塞酸增强磁共振成像的影像学特征预测肝细胞癌患者经动脉化疗栓塞治疗的耐药性。
Acta Radiol. 2021 Dec;62(12):1548-1558. doi: 10.1177/0284185120971844. Epub 2020 Nov 16.
9
The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.钆塞酸二钠增强磁共振成像与多排螺旋 CT 增强扫描诊断肝细胞癌的效能:八项前瞻性研究的荟萃分析。
Eur Radiol. 2019 Dec;29(12):6519-6528. doi: 10.1007/s00330-019-06294-6. Epub 2019 Jun 27.
10
Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging.第七届肝脏磁共振成像国际论坛共识报告
Eur Radiol. 2016 Mar;26(3):674-82. doi: 10.1007/s00330-015-3873-2. Epub 2015 Jun 13.

本文引用的文献

1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.临床实践中阿替利珠单抗联合贝伐珠单抗治疗 HCC 的可重现安全性和疗效:AB-real 研究结果。
Eur J Cancer. 2022 Nov;175:204-213. doi: 10.1016/j.ejca.2022.08.024. Epub 2022 Sep 20.
3
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials.
比较不可切除肝细胞癌新型联合治疗策略的疗效:III 期试验的网络荟萃分析。
Eur J Cancer. 2022 Oct;174:57-67. doi: 10.1016/j.ejca.2022.06.058. Epub 2022 Aug 12.
4
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity.肝细胞癌的立体定向体部放射治疗:从起步到不断成熟。
JHEP Rep. 2022 May 14;4(8):100498. doi: 10.1016/j.jhepr.2022.100498. eCollection 2022 Aug.
5
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.肝移植和降期治疗肝细胞癌的十年结果。
JAMA Surg. 2022 Sep 1;157(9):779-788. doi: 10.1001/jamasurg.2022.2800.
6
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.卡博替尼联合阿替利珠单抗与索拉非尼治疗晚期肝细胞癌(COSMIC-312):一项多中心、开放标签、随机、III 期临床试验。
Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
7
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.PD-1 抑制与经动脉化疗栓塞联合治疗肝细胞癌:回顾性倾向评分匹配研究中安全性和疗效的评估。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-004205.
8
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?临床试验中的新型免疫治疗联合方案治疗肝细胞癌:它们会改变未来的治疗格局吗?
Expert Opin Investig Drugs. 2022 Jul;31(7):681-691. doi: 10.1080/13543784.2022.2072726. Epub 2022 May 6.
9
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.肝癌患者免疫检查点抑制剂停药后的后续治疗模式和结局。
Hepatol Commun. 2022 Jul;6(7):1776-1785. doi: 10.1002/hep4.1927. Epub 2022 Apr 28.
10
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.阿替利珠单抗联合贝伐珠单抗治疗伴有 A 级和 B 级肝硬化的肝细胞癌患者的安全性和耐受性的初步证据:一项真实世界研究。
Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8.